- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Multiple Myeloma | Clinical
test
ODAC Votes Against Melphalan Flufenamide in R/R Multiple Myeloma
September 22, 2022
Due to the potential detriment in overall survival, its failure to demonstrate a progression-free survival benefit, and the lack of a known appropriate dose, ODAC has voted that melphalan flufenamide is not favorable in relapsed/refractory multiple myeloma.
Gasparetto Discusses Sequencing Selinexor in Relapsed/Refractory Multiple Myeloma
September 21, 2022
During a Targeted Oncology case-based roundtable event, Cristina Gasparetto, MD, discussed data supporting the use of selinxor for patients with relapsed/refractory multiple myeloma.
Behind the FDA Approvals of BCMA-Directed Therapies for Multiple Myeloma
September 16, 2022
Adam Cohen, MD, discusses the current FDA-approved BCMA-directed therapies in the multiple myeloma space and the clinical data supporting each agent.
Dara-KRd Leads to Encouraging Responses in Newly Diagnosed Multiple Myeloma
September 08, 2022
The phase 2 MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone demonstrates the promise of minimal residual disease surveillance in newly diagnosed multiple myeloma with 0 or 1 high-risk cytogenetic abnormalities
Using Frontline Quadruplet Therapy for Transplant-Eligible Multiple Myeloma
September 02, 2022
During a live virtual event, Brea C. Lipe, MD, discussed what considerations affect the choice of triplet or quadruplet therapy for a patient with transplant-eligible multiple myeloma.
IMS Studies Utilize CoMMpass Genomic Data in Multiple Myeloma Research
August 31, 2022
The CoMMpass genomic data set of patients with multiple myeloma was utilized by investigators, contributing to 19 abstracts reported at the International Myeloma Society.
Durable Response Shown With Cilta-cel in Heavily-Pretreated, Lenalidomide-Refractory Myeloma
August 28, 2022
The phase 2 CARTITUDE study showed encouraging response in the heavily-pretreated multiple myeloma population. Now, the phase 3 CARTITUDE-4 trial is underway.
Resistance to BCMA-Directed Therapies Correlates with Biallelic Deletion of TNFRSF17 in Myeloma
August 28, 2022
An association between biallelic deletion of TNFRSF17 and resistance to therapies like chimeric antigen receptor T cells and T-cell engagers has been identified in myeloma.
Dara-RVd Reduces Risk of Progression or Death in Transplant-Eligible NDMM
August 28, 2022
The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.
ABBV-383 Shows Promising Efficacy, Safety in Pretreated Multiple Myeloma
August 28, 2022
Results of a phase 1 trial of the bispecific antibody ABBV-383 showed a high overall response rate and manageable adverse event profile in patients with relapsed/refractory multiple myeloma.